NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.

Authors

Helen Mackay

Princess Margaret Cancer Centre, Toronto, ON, Canada

Helen Mackay , Bj Rimel , David Bender

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.

First Author: B.J. Rimel

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.

First Author: Bradley Corr

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

First Author: Camille Catherine Jackson